GCCL (Global Clinical Central Lab) successfully hosted the IR Pitching & Networking Event 2025
on October 16 during BIX 2025 (BIOPLUS-INTERPHEX KOREA) at Coex, Seoul.
The event was designed to promote collaboration between Korean biotech innovators, investors, and global clinical development partners
— strengthening the bridge between research, innovation, and investment.
The event began with a welcome address from GCCL’s CEO, KwanGoo Cho,
who emphasized the importance of fostering meaningful connections between science, innovation, and investment in Korea’s rapidly advancing biotech sector.
He highlighted the role of GCCL as a global hub for clinical excellence and reaffirmed the company’s commitment to its vision
— “Connecting Science, Bridging Innovation.”
Following the opening, YuHwa Choi, Head of Business Operations Division, introduced GCCL’s core business and scientific capabilities,
highlighting the company’s GCLP-certified central lab services, bioanalytical lab and R&D expertise,
and its role as a leading APAC-based central lab supporting global clinical trials.
Her session also showcased real-world examples of multinational partnerships,
illustrating how GCCL supports clients as an end-to-end analytical partner throughout global clinical development.
Session 1 | IR Pitching Session
The first session featured IR pitching presentations from seven Korean biotech companies,
each delivering a five-minute overview of their pipelines and innovative research directions.
Presenting companies included
MTHERA PHARMA, VSPharmTech, SiALBIO, Digmbio Inc., EpiBiotech, Threebrooks, and Exollence Biotechnology.
The presentations from these seven innovative Korean biotech companies not only captured the attention of investors and industry professionals,
but also demonstrated the rapidly growing strength and competitiveness of Korea’s biotech research and development ecosystem.
Through their cutting-edge technologies, strategic pipelines, and visionary approaches,
these companies are showing that Korea is becoming a significant player in global biotechnology and clinical innovation.
The event provided a tangible showcase of how domestic biotech firms are aligning with international standards,
engaging in advanced research, and positioning themselves to contribute meaningfully to the global life sciences landscape.
Such dynamic presentations reinforce the message that Korea’s biotech sector is not only expanding in scale
but also increasing in sophistication, innovation capacity, and global relevance,
paving the way for stronger collaborations with international partners and investors.
Session 2 | Networking Session
The second session centered on networking,
where biotech representatives, investors, and clinical professionals exchanged ideas and explored opportunities for future collaboration.
Discussions covered diverse topics such as partnership models, clinical trial cooperation, and global expansion strategies
— creating meaningful connections across the biotech ecosystem.
Many participants remarked that the networking session went beyond standard industry meetups,
highlighting its value as a rare forum that effectively connects innovation with strategic decision-making.
It also provided a platform for building long-term relationships, as investors and companies identified mutual opportunities and next steps for partnership.
Overall, the session reinforced GCCL’s commitment to fostering a collaborative biotech ecosystem,
helping domestic innovators gain visibility and access to international networks while strengthening the overall clinical research landscape in Korea.
Through this event, GCCL reaffirmed its role as a connector of innovation and collaboration within the clinical research community.
By bridging Korean biotech innovators with international partners,
GCCL remains committed to advancing scientific excellence and strengthening global partnerships
that accelerate progress in biotech and clinical development.
P.S. GCCL's Booth Participation at BIX 2025
In addition to hosting the IR Pitching & Networking Event, GCCL also participated as a Gold Sponsor at BIX 2025 throughout the three-day exhibition.
The company showcased its capabilities and service offerings at a spacious, standalone booth,
providing visitors with detailed information on global clinical sample analysis, bioanalytical services, and partnership opportunities.
The booth served as an interactive hub where attendees could engage with GCCL experts, explore case studies,
and learn about the company’s end-to-end support for multinational clinical trials.
This presence further emphasized GCCL’s leadership in the APAC region and its commitment to connecting biotech innovation with global clinical development.
We will always continue to be the best clinical trial partner for our customers.
Click the banner below to learn more about GCCL!
> About GCCL > Newsroom > Company News